Objective: We present 2 patients who were identified with mutations in the GPR98 gene that causes Usher syndrome type 2 (USH2). Methods: One hundred ninety-four (194) Japanese subjects from unrelated families were enrolled in the study. Targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes were used to identify the genetic causes of hearing loss. Results: We identified causative mutations in the GPR98 gene in 1 family (2 siblings). The patients had moderate sloping hearing loss, and no progression was observed over a period of 10 years. Fundus examinations were normal. However, electroretinograms revealed impaired responses in both patients. Conclusion: Early diagnosis of Usher syndrome has many advantages for patients and their families. This study supports the use of comprehensive genetic diagnosis for Usher syndrome, especially prior to the onset of visual symptoms, to provide the highest chance of diagnostic success in early life stages.
Introduction
Usher syndrome (USH) is an autosomal recessive disorder characterized by hearing loss (HL), retinitis pigmentosa (RP), and vestibular dysfunction. There are 3 clinical subtypes classified by the severity and onset of HL, onset of RP, and vestibular symptoms. However, it can be difficult to recognize these clinical manifestations due to its extremely heterogeneous nature. USH type 1 (USH1) has the most severe forms that are characterized by congenital profound HL, prepubertal onset RP, and absent vestibular responses. USH type 2 (USH2) shows congenital moderate to severe with a high-frequency sloping HL and normal vestibular functions. The onset of RP is later than in USH1, and visual symptoms such as night blindness in USH2 usually occur in the second decade. USH type 3 (USH3) has variable onset and severity in these 3 manifestations. 1, 2 Due to its complexity, diagnosis of USH in childhood, based on clinical phenotype, can be difficult because patients appear to have only nonsyndromic HL in childhood and RP develops in later years. Based solely on frequency, if a patient has only HL, it is hard to diagnose accurately syndromic HL.
Early diagnosis has many immediate and several longterm advantages for patients and their families and is now possible through genetic testing. 1 The advantage of genetic testing for the diagnostic approach to USH has been fully established. We also previously reported a case in which MYO7A mutation analysis allowed the diagnosis of USH1 in advance of the appearance of the visual symptoms, and genetic testing allowed us to give appropriate genetic counseling. 3 To date, 10 corresponding genes have been identified as a cause of USH: MYO7A (USH1B), USH1C (USH1C), CDH23 (USH1D), PCDH15 (USH1F), USH1G (USH1G), and CIB2 (USH1J) for USH1, USH2A (USH2A), GPR98 (USH2C), and DFNB31 (USH2D) for USH2, and CLRN1 (USH3A) for USH3. 4 However, these targeted genes are significant in size and number of exons, and much labor and expense are necessary for analyzing whole genes corresponding to USH. Recent advances in targeted genomic enrichment with massively parallel sequencing (TGE+MPS) have made possible the sequencing of all known causative genes simultaneously. 5, 6 In this study, we performed genetic testing on 194 Japanese hearing loss patients. Here, we describe 2 patients with hearing loss in whom we identified novel mutations in the GPR98 gene. Based on the result of genetic testing, we performed ophthalmological tests for the patients and diagnosed USH2 even before they suffered from any visual symptoms. This is the first report of a diagnosis of USH2 caused by GPR98 mutations in advance of visual defects in the cohort of nonsyndromic HL patients and highlights the importance of comprehensive genetic testing for use in the clinical diagnosis of hearing loss patients.
Subjects and Methods

Subjects
One hundred ninety-four (194) Japanese subjects (114 females) from unrelated and non-consanguineous families were ascertained through 33 otolaryngology clinics in 28 prefectures across Japan. All subjects had presumed nonsyndromic HL. For each proband, informed consent was obtained to participate in this study, which was approved by the human subjects ethical committee associated with each clinic.
Clinical information and blood samples were obtained for each proband and for all consenting affected and unaffected relatives.
Targeted Genomic Enrichment and Massively Parallel Sequencing
Genomic DNA was assessed for quality by gel electrophoresis and spectrophotometry (Nanodrop 1000; Thermo Fisher Scientific, Waltham, Massachusetts, USA; 260/280 ratio of 1.8-2.2) and for quantity by fluorometry (Qubit 2.0 Fluorometer; Life Technologies, Carlsbad, California, USA). TGE of all exons of all genes implicated in nonsyndromic HL, including nonsyndromic HL mimics, was completed as described, targeting 89 genes as part of the OtoSCOPE v5 platform. Libraries were prepared using a modification of the solution-based Agilent SureSelect target enrichment system (Agilent Technologies, Santa Clara, California, USA). 7 Of the 194 samples, 58 samples were processed manually; the remainder was prepared robotically using the Sciclone NGS Workstation.
In brief, 3 μg gDNA was randomly fragmented to an average size of 250 bp (Covaris Acoustic Solubilizer; Covaris Inc, Woburn, Massachusetts, USA), fragment ends were repaired, A-tails were added, and sequencing adaptors were ligated before the first amplification. Solid phase reverse immobilization purifications were performed between each enzymatic reaction. Hybridization and capture with RNA baits was followed by a second amplification before pooling for sequencing. Minimal amplification was used-typically 8 cycles for the pre-hybridization polyremase chain reaction (PCR; range, 8-10 cycles) using NEB Phusion HF Master Mix (New England BioLabs Inc, Ipswich, Massachusetts, USA) and 14 cycles for the post-hybridization PCR (range, 12-16 cycles) using Agilent Herculase II Fusion DNA Polymerase. All samples were barcoded and multiplexed before sequencing on either an Illumina MiSeq or HiSeq (Illumina Inc, San Diego, California, USA) in pools of 4 to 6 or 48, respectively, using 100-bp paired-end reads.
Bioinformatics Analysis
Data were analyzed as described using a local installation of the open-source Galaxy software and the following opensource tools: BWA 8 for read mapping, Picard for duplicate removal, GATK 9 for local re-alignment and variant calling and NGSRich 10 for enrichment statistics. 6 We reported and annotated variants with custom software.
Variant Confirmation
All pathogenic variants were confirmed by Sanger sequencing and segregation analysis using exon-specific custom primers.
Results
Mutation Analysis
We indentified novel causative mutations including 1 frameshift mutation and 1 missense mutation in GPR98 in the cohort of this study (194 hearing loss patients). The former mutation corresponded to c.16604_16611delGTACCCAG (NM_032119) and led to a frame-shift mutation and truncation (p.Ser5535ArgfsX6). The second mutation was c.9464C>A (p.Ala3155Asp). We also performed Sanger sequencing for the family segregation study and confirmation of the variant MPS outputted result. As shown in Figure  1 , Sanger sequencing results revealed that the parents had 1 of either mutation in the heterozygote, and the proband's brother had biallelic mutations.
Case Details
The proband is a 16-year-old female (II-2; SNS 3356). She had no complications in the perinatal period. She had not undergone newborn hearing screening. At the age of 6, HL was suspected at an elementary school wellness check-up, and she was referred to Shinshu University Hospital, Department of Otolaryngology for audiological examinations. An older brother (II-1; SNS 3357) (8 years old) visited the hospital at the time she received her consultation as he had not undergone newborn hearing screening. They were diagnosed with moderate HL, with a high-frequency sloping configuration (Figures 2A, 3A) . Subsequently, they began to wear hearing aids. No subsequent deterioration in their HL was observed over a period of 10 years (Figures 2A, 3A) .
They participated in this study in 2004; however, we could not find the responsible genes within the common genes, such as GJB2 and mitochondrial 1555AG mutations. Genetic testing using MPS was carried out in 2013. Mutations in the GPR98 gene as mentioned previously were detected, thus we considered that they might have USH2C rather than nonsyndromic HL. At the time of testing, the brother (II-1) was aware of night blindness at the age of 18. However, the proband (II-2) had no apparent nyctalopia or dark adaptation problems at the age of 16. Ophthalmological testing showed that the fundus examinations of both patients were normal (Figures 2C, 3C ). However, his electroretinogram (ERG) revealed a complete bilateral absence ( Figure 3D ), and her ERG revealed a weaker response than that of normal levels ( Figure 2D ).
In addition, their vestibular functions (determined by means of caloric tests and cervical vestibular evoked myogenic potential [cVEMP]) were both normal ( Figures 2B,  3B ). With these findings, they were diagnosed with USH2C caused by GPR98 mutations.
Discussion
In this report, we identified novel heterogygous mutations in the GPR98 gene among autosomal recessive inherited and presumably nonsyndromic HL and finally diagnosed USH2C. One (p.Ser5535ArgfsX6) was considered pathogenic due to a truncating mutation. The second (p.Ala3155Asp) was strongly suspected as pathogenic, and this mutation was not described in any mutation databases. PhyloP and GERP showed this residue is well conserved among various species. We also employed functional prediction software (Polyphen2, SIFT, Mutation Taster, and LRT) that indicated the second mutation to be damaging (1.00, 0.00, 0.99, and 1.00, respectively).
The GPR98 gene (also previously known as the VLGR1 gene) is localized on chromosome 5q13 and contains 90 exons and has a range of 600 kb. GPR98 was first implicated in USH2 in 2004. 11 Weston et al 11 identified mutations in GPR98 among patients who had deaf-blindness, and also showed that the expression of GPR98 was observed in human fetal retina and cochlea by RT-PCR. Subsequently, there have been several cases identified, thus, it was considered to be a USH2 causative gene. [12] [13] [14] Mutations of some USH causative genes (MYO7A, USH1C, CDH23, PCDH15, CIB2, DFNB31) can result in both nonsyndromic hearing loss and USH, 4 while mutations of the GPR98 gene are only responsible for USH. The GPR98 protein (VLGR1) is one of the major components of the ankle link of the hair bundle in the cochlea 15 and plays an important role in the normal development of cochlea hair bundles. 16 McGee et al 16 reported that Vlgr1 mutated mice exhibited early hair bundle defects resulting in hearing loss at high frequencies, whereas normal vestibular function was observed. Normal transduction currents were measured in vestibular hair cells. These findings are also consistent with our present cases that have normal vestibular functions. A B WT c.9464C>A In USH2 patients, USH2A (USH2A) has been reported as the most common USH2 genetic subtype (57%~95.8%), [17] [18] [19] while USH2C (GPR98) and USH2D (DFNB31) accounted for approximately 5.2% to 19% and 0% to 9.5%. 14, [17] [18] [19] All published mutations in USH genes have been recorded in the public database, USHbases. 20 Nakanishi et al 21 reported the frequency of USH2 genetic subtypes in Japanese USH patients and that USH2A gene mutations were found in 8 of 10 patients (80%). Our study is the first to identify the GPR98 gene mutations. However, we recruited a cohort of suspected nonsyndromic HL patients, so that the frequency of USH2C in a Japanese population is still unclear.
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Abadie et al 22 reported that in USH2C, moderate HL was predominant (76%), and a gently down-sloping configuration characterized most audiograms (66%). This is consistent with our cases. It has been shown that USH2C patients had more severe HL than USH2A; however, it is impossible to predict the candidate gene based on audiograms due to the heterogeneity of USH. 22 This is the first report of mutations in GPR98 identified by genetic testing using MPS in which we were able to diagnose USH2C before the patients suffered from obvious visual symptoms. With regard to USH2C patients, the median age of HL diagnosis was 5 years, although the median age at which USH2 was diagnosed was 34.5 years. 22 That is because visual symptoms with RP appear later in life, mostly in the second decade. 23 In general, diagnosis of RP can be possible before the appearance of visual symptoms by ERG 24 ; however, there is usually no indication to carry out an ERG before RP symptoms appear. Based on the present cases, we suggest that if mutations are found in genes concerned with USH, ophthalmological testing should be provided to the patients for differential diagnosis. We previously recommended ophthalmologic tests for young nonsyndromic HL patients in whom candidate mutations in the USH gene had been found. 3 Further evolution of genetic testing, such as MPS, will make more accurate diagnosis of HL possible, but we should also be more rigorous in confirmation of the phenotypes, including hearing loss and other manifestations. Regarding HL caused by mutations in GPR98, all clinicians should provide optimal management of hearing abilities in order to improve patient's quality of life. We should provide genetic counseling to patients about the risk of future vision loss and also provide applicable educational support.
In conclusion, this study supports the use of comprehensive genetic diagnosis for USH, particularly in advance of visual symptoms, to provide the highest chance of diagnostic success in the early life stages. The benefit of early identification lies in the potential to provide future treatment to prevent RP. 1 Genetic diagnosis using MPS will contribute to early intervention and may provide an opportunity for the development of novel therapeutic possibilities.
